tbuckley/cabot-search huggingface dataset:
A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Authors: Iman Aboudalle, Marina Y Konopleva, Tapan M. Kadia, Kiran Naqvi, Kenneth Vaughan, Mehmet Kurt, Antonio Cavazos, Sherry A. Pierce, Koichi Takahashi, Lucia Masarova, Musa E. Yilmaz, Elias Jabbour, Guillermo Garcia-Manero, Steven M. Kornblau, Farhad Ravandi, Jorge Cortes, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood (2019)
BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
Authors: Sasanka M. Handunnetti, Chloe Pek Sang Tang, Tamia Nguyen, Xing Zhou, Ella Thompson, Hanzi Sun, Haimei Xing, Bo Zhang, Yin Guo, Lesley Ann Sutton, Paolo Ghia, Richard Rosenquist, Lydia Scarfo, Silvia Bonfiglio, John F. Seymour, Mary Ann Anderson, Andrew W. Roberts, David C.S. Huang, Ye Liu, Chan Y. Cheah, David Alan Westerman, Paul Sung-Hao Yeh, Constantine S. Tam, Piers Blombery
Journal: Blood (2019)
EXTH-14. PULSED ELECTRIC FIELDS FOR THE TREATMENT OF BRAIN TUMORS
Authors: Shirley Sharabi, David Last, Dianne Daniels, Itzik Cooper, Yael Bresler, Yael Mardor
Journal: Neuro-Oncology (2019)

Abstract When high pulsed electric fields (PEFs) are applied to the brain electroporation occurs. Depending on the electric fields strength, irreversible electroporation, inducing necrotic cell death or reversible electroporation, inducing BBB disruption may occur. We have developed a unique minimally-invasive setup for treating brain tumors employing a single insulated intracranial electrode with an exposed tip placed within the tumor and an external surface electrode. This unique setup, termed point-source electroporation, provides intratumoral irreversible-electroporation (inducing necrosis) with surrounding reversible BBB disruption, enabling efficient delivery of systemically administered drugs into the infiltrating zone. Treatment duration is 1–2 min. An efficacy study conducted with 120 glioma-bearing rats resulted in suppressed tumor growth rates in the electroporation+Cisplatin group (1.1±0.1) relative to growth rates in the control group (5.2±1.0), p&lt; 0.047, and in the Cisplatin-only group p&lt; 0.012 (3.92±1.0) (Welch’s F(2,12.73)=10.84; p&lt; 0.002; ω2=0.28). Kaplan-Meir analysis revealed that electroporation+Cisplatin prolonged survival significantly (χ2=7.54; p&lt; 0.006). Immunofluorescence analysis revealed significant infiltration of peripheral macrophages and CD8+ cells in the residual tumor. A finite elements simulation demonstrated the feasibility for obtaining clinically-relevant treatment volumes (~6cm diameter) using a single 3mm (diameter) intracranial catheter. Additionally, we discovered that low PEFs, an order of magnitude lower than electroporation threshold, can also transiently disrupt the BBB by a different mechanism, enabling penetration of both small (Gd/NaF) and large (Evans blue bound to serum albumin) molecules and immune cells, non-invasively. The extent of BBB disruption, measured in mice using delayed-contrast MRI, was found to be linearly dependent both on the electric field strength (r2=0.9,p&lt; 0.03) and on the number of applied pulses (r2=0.94,p&lt; 0.003). These results demonstrate the feasibly of applying combined systemic chemotherapy with point-source electroporation, a minimal-invasive/rapid treatment of PEFs, for obtaining significant antineoplastic effects. Furthermore, low PEFs may be applied non-invasively, rapidly and repeatedly for obtaining reversible BBB disruption.
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Authors: Neha Mehta-Shah, Peter A. Riedell, Nancy L. Bartlett, Amanda F Cashen, Brad S. Kahl, Todd A Fehniger, Chaz Moreno, Jingxia Liu, Kenneth R. Carson
Journal: Blood (2019)
Platelet-Delivered Recombinant ADAMTS13 Inhibits Platelet Adhesion and Aggregation on Collagen Surface Under Flow in the Presence of Autoantibodies from Acquired Thrombotic Thrombocytopenic Purpura
Authors: Mohammad S. Abdelgawwad, Jenny K. McDaniel, Wenjing Cao, Huy P. Pham, Lance A. Williams, X. Long Zheng
Journal: Blood (2016)
Combination of Gatekeeper Mutations and Cysteine 481 Replacement Causes Super Resistance to the Irreversible BTK Inhibitors Ibrutinib, Acalabrutinib and Zanubrutinib
Authors: Hernando Yesid Estupiñan Velasquez, Yuye Shi, Dara K. Mohammad, Qing Wang, Mauno Vihinen, Rula Zain, Anna Berglöf, Edvard CI Smith
Journal: Blood (2019)
The Search for a Universal Flu Vaccine Heats Up
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status
Authors: Agrima Mian, Albert Aboseif, Wei Wei, Rajshekhar Chakraborty, Jack Khouri, Joslyn Rudoni, Allison M. Winter, Sonam Patel, Deepa Jagadeesh, Robert M. Dean, Brad Pohlman, Stephanie Berg, James R. Cook, Brian T. Hill, Alex V. Mejia Garcia
Journal: Blood (2019)
Identifying and Preventing Adverse Childhood Experiences
Authors: Christopher M. Jones, Melissa T. Merrick, Debra E. Houry
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide
Authors: Ignacio Gómez-Centurión, Nieves Dorado, Rebeca Bailén, Miguel Echenagusia, Arturo Alvarez, Gillen Oarbeascoa, Cristina Muñoz, Javier Anguita, Jose L. Diez-Martin, Mi Kwon
Journal: Blood (2019)
Chronic Health Conditions and Late Mortality Among Survivors of Childhood Acute Myeloid Leukemia: A Report from the Childhood Cancer Survivor Study (CCSS)
Authors: Lucie M Turcotte, John A Whitton, Wendy M. Leisenring, Todd Gibson, Rebecca M Howell, Kevin R. Krull, Joseph P. Neglia, Kevin C Oeffinger, Kirsten K. Ness, William G. Woods, E. Anders Kolb, Leslie L. Robison, Gregory T Armstrong, Eric J Chow
Journal: Blood (2019)
Considerations on medical training for gender-affirming care: Motivations and perspectives
Authors: Shanna Duffy Stryker, Harini Pallerla, Sarah Pickle
Journal: International Journal of Transgender Health (2019)

Background: Many transgender individuals lack access to needed medical care, partially due to a lack of providers with experience in gender-affirming healthcare.Aims: The purpose of this study was to identify professional motivators for medical providers seeking out training in gender-affirming care and to define which training experiences were most beneficial to their career development. By identifying experienced providers' recommendations on which training modalities are most relevant to their practice, we aim to suggest future directions for medical education initiatives to effectively expand the transgender care workforce.Methods: A voluntary cross-sectional electronic survey was distributed through professional listservs and publicly-available referral lists to interdisciplinary providers who self-identified as having experience in providing care to transgender individuals.Results: One hundred and fifty-three (n = 153) physicians, physician assistants, or advance-practice nurses responded to the survey. The majority (96.7%) were located in the United States, representing 37 states. The two most common motivators for seeking out training in gender-affirming care were filling a need in the community (73.0%) and/or having met a transgender-identified person in a clinical setting who requested care (63.8%). While many providers gained skills independently (57.3%), the two most commonly-available training opportunities were professional conferences (57.3%) and mentorship (41.3%). Respondents were most likely to recommend that others in their field be trained via structured clinical experience (e.g., a rotation or longitudinal exposure during training), rather than additional didactic training.Discussion: This study identifies key high-yield training methodologies which could improve access to quality gender-affirming healthcare. Through integration of structured clinical experiences during training, direct clinical mentorship, and professional development at conferences on gender-affirming care, the workforce of welcoming and prepared healthcare providers for transgender patients will increase. This will lead to a tremendous improvement on access to gender-affirming care in our communities.
NIMG-39. REVEALING THE TUMOR-IMMUNE LANDSCAPE THROUGH SPATIALLY-RESOLVED RADIOMICS: CASE STUDIES
Authors: Andrea Hawkins-Daarud, Hyunsoo Yoon, Dileep Monie, Kyle Singleton, Sara Ranjbar, Nhan Tran, Behnam Badie, Russell Rockne, Christine E Brown, Leland Hu, Jeff Bruce, Peter D Canoll, Jing Li, Kristin Swanson
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Conventional magnetic resonance imaging (MR) guides patient care in GBM. However, there is mounting awareness that MR enhancement is non-specific reflecting either tumor progression or non-tumoral inflammatory changes. Histological evaluation of GBM is held as the gold standard for disease assessment. However, the invasiveness of this methodology and the sample sparsity limit its usefulness. Methods to infer histological underpinnings of MRI are needed to improve clinical care. METHODS A transfer learning mixed effects model based on T1Gd and FLAIR MR voxel based image features trained and cross-validated to predict FPKM values of CD68, CASP3, CD8A and IL13RA2. Training data included RNAseq from 38 image-localized biopsies from 15 newly-diagnosed GBM patients. These models were then applied to two independent patients, chosen based on therapy and the quality of image registration, at three different time points, just prior to receiving IL13RA2 targeted CAR-T therapy for rGBM, after 2 cycles and after 4 cycles, resulting in a voxel-based prediction of the relative expression levels of these genes. RESULTS Cross-validation of the proposed machine learning models demonstrated a Pearson Correlation coefficient between predicted and observed FPKM values of 0.89 (CD68), 0.92 (CASP3), 0.93 (CD8A), and 0.88 (IL13RA2). When the models were applied to the two CAR-T patients, CD68-modeled expression levels were seen to increase throughout therapy for one patient, while remaining stable for the other. Survival from first CAR-T infusion was, respectively, 412 and 83 days suggesting that the increased CD68 was indicative of therapeutic effectivity. Further, the spatial activity predictions were consistent with expected therapeutic action as the correlation coefficient between CASP3 and the product of IL13R2 and CD8A expression was 0.81, suggesting the T-cells targeting IL13RA2 were inducing cell death. CONCLUSIONS Preliminary results with our model highlights the potential of spatially resolved radiomic maps to provide insight into regional therapeutic effectivity.
BCR-Induced VLA-4 Activation in the TCL1 Transgenic Mouse Model for Chronic Lymphocytic Leukemia
Authors: Eva Szenes, Andrea Härzschel, Erika Tissino, Pischeli Justine, Julia Gutjahr, Sandra Pennisi, Jan Höpner, Alexander Egle, Nadja Zaborsky, Marie Follo, Sarah Decker, Christine Dierks, Alexandre Chigaev, Antonella Zucchetto, Valter Gattei, Richard Greil, Tanja Nicole Hartmann
Journal: Blood (2019)
Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing
Authors: James B Smadbeck, Beth A Pitel, Kathryn E. Pearce, Sarah H Johnson, Nicole Hoppman, Rhett P. Ketterling, Patricia Griepp, Linda B Baughn, George Vasmatzis, Jess Peterson
Journal: Blood (2019)
A Case of Thrombosis of the Abdominal Aorta
Authors: W. Bell
Journal: BMJ (1896)

by a thorough washing with weak carbolic lotion and a large double tube was inserted.May 20th.The cavity has been regularly irrigated, and there is little discharge.May 29th.Sinus still open.June 8th.One and a-half inch single tube still in.Very little discharge
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis
Authors: Ariel F Grajales-Cruz, Cristian Ivan Rodriguez Arocho, Ashley Rose, Jamie Shapiro, Elizabeth Finley-Oliver, Kenneth H. Shain, Jason B. Brayer, Taiga Nishihori, Leonel Ochoa, Omar Alexis Castaneda Puglianini, Melissa Alsina, Rachid Baz
Journal: Blood (2019)
The Small Molecule IODVA1 Inhibits the Rac Guanine Nucleotide Exchange Factor Vav3 and Overcomes TKI-Resistance in Ph+(BCR-ABL1) B-ALL
Authors: Nicolas Nassar, Shailaja N Hegde, Anjelika Gasilina, Mark Wunderlich, Gurdat Premnauth, Edward Merino, Yuan Lin, Reza Ahmadian, Yi Zheng, Benjamin Mizukawa, Lisa Privette Vinnedge, Jose A Cancelas
Journal: Blood (2019)
Potential Influence of Hematological or Immunological Hereditary Predisposition Genes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
Authors: Zhihui Li, Qinlong Zheng, Yongqiang Zhao, Yanzhi Song, Fan Yang, Min Jiang, Chunrong Tong, Tong Wu
Journal: Blood (2019)
Abstract 13503: Environmental and Socioeconomic Factors Influence the Incidence of Congenital Heart Disease: A Population-Based Study in California
Authors: Shabnam Peyvandi, Rebecca Baer, Christina Chambers, Mary Norton, Satish Rajagopal, Kelli Ryckman, Anita Moon-Grady, Laura Jelliffe-Pawlowski, Martina A Steurer
Journal: Circulation (2019)

Introduction: The development of congenital heart disease (CHD) is multifactorial with genetic and environmental influences. We sought to determine the relationship between socioeconomic (SE) and e...
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma
Authors: Akash Mukherjee, Denái R. Milton, Alison Gulbis, Celina Ledesma, Elias Jabbour, Amin M. Alousi, Qaiser Bashir, May Daher, Betul Oran, Amanda L. Olson, David Marin, Samer Srour, Partow Kebriaei, Rohtesh S. Mehta, Kathie P Nemeth, Uday Popat, Jin S Im, Richard E. Champlin, Issa F. Khouri
Journal: Blood (2019)
Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair
Authors: Kidist Ashami, Sena Kim, Ravi Vij, Julie K. Ritchey, Srikanth Santhanam, Sora Lim, Sarah Peterson, Matthew Ciorba, John F. DiPersio, Jaebok Choi
Journal: Blood (2019)
Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
Authors: Amandeep Salhotra, Liana Nikolaenko, Lu Chen, NI-Chun Tsai, Diane Lynne Smith, Auayporn P. Nademanee, Leslie L. Popplewell, Alex F. Herrera, Matthew Mei, Stephen J. Forman, Jasmine M. Zain
Journal: Blood (2019)
Abstract 13870: Defining the Predictive Values of Three Different Platelet Function Testing for The Status of the Cyp2c19 Phenotype in Patients Undergoing Percutaneous Coronary Intervention
Authors: Hongzhe Zhang, Moo Hyun Kim, Tae Ho Park, Jong Seong Park, Kyung Il Park
Journal: Circulation (2012)

Introduction: Published data suggests that the carrying of loss of function (LOF) CYP2C19*2 or *3 alleles is indicative of increased residual platelet aggregation and a higher risk of adverse cardi...
COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting
Authors: Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, Luigi Marcheselli, Robel Papotti, Elisa Forti, M. Christina Christina Cox, Arianna Di Napoli, Tamar Tadmor, Antonino Maiorana, Valentina Donati, Sara Galimberti, Stefano Sacchi
Journal: Blood (2019)
NUP98-KDM5A Fusion Induces Hematopoietic Cell Proliferation and Alters Myelo-Erythropoietic Differentiation
Authors: Jonathan Miller, Ryan Hiltenbrand, Tamara Lamprecht, Aman Seth, Sherif Abdelhamed, Ilaria Iacobucci, Charles G. Mullighan, Jeffery M. Klco
Journal: Blood (2019)
HOUT-15. IDENTIFICATION AND CHARACTERIZATION OF CARDIAC EVENT ABNORMALITIES IN PATIENTS WITH CRANIOPHARYNGIOMA
Authors: Christa Seligman, Rebecca Harrison, Saamir Hassan, Jimin Wu, John DeGroot, Shaan Raza
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Craniopharyngiomas (CP) are frequently associated with a malignant clinical trajectory despite their benign histology. This population frequently has endocrinopathies and autonomic dysfunction due to tumour location, which may influence cardiac function and long term health outcome. In this study, we evaluated for clinical and paraclinical cardiac abnormalities in adult and pediatric patients with craniopharyngioma. METHODS We retrospectively identified patients in our neurosurgery database with a diagnosis of craniopharyngioma that received neurosurgery at MD Anderson Cancer Center. We queried the medical record for demographic and disease-related information, as well as clinical information regarding cardiac risk factors. Perioperative electrocardiograms (EKGs) were analyzed where available. RESULTS We identified 56 patients with craniopharyngioma, 27 (48.2%) of which were female. Average age was 39 years, and all patients had undergone subtotal (49.1%), gross total (32.7%), or near gross total (18.2%) resection. Over half (53.6%) had undergone radiation, none had received systemic therapy, and 1 (1.8%) intra-cystic chemotherapy. The majority had adamantanomatous-type histology (83%) and the remainder papillary (17%). At diagnosis, average BMI was elevated at 30.98. Hypertension (30.4%), diabetes mellitus (32.1%), and thyroid dysfunction (80%), were found in this cohort. Nearly a quarter (23.2%) were on statin therapy for dyslipidemia. Stimulant (14.3%) and neuropleptic (3.6%) use were also identified. Of patients with perioperative EKG performed (N= 39), 30 were available for review. Of these, patients were identified with abnormal rate (N=9, 30.0%), PR interval (N=2, 6.7%), QRS interval (N=4, 13.3%), and QTc interval (N=1, 3.3%). Some patients presented with a history of heart palpitations (1.8%) and syncopal episodes (3.6%), but not chest pain. CONCLUSION This analysis demonstrates frequent vascular and cardiac risk factors in patients with craniopharyngioma. We advocate for increased awareness of cardiac health in this young population. Further prospective evaluation is warranted to better understand cardiac health in this patient group.
FOXM1 drives proximal tubule proliferation during repair from acute ischemic kidney injury
Authors: Monica Chang-Panesso, Farid F. Kadyrov, Matthew Lalli, Haojia Wu, Shiyo Ikeda, Eirini Kefaloyianni, Mai M. Abdelmageed, Andreas Herrlich, Akio Kobayashi, Benjamin D. Humphreys
Journal: Journal of Clinical Investigation (2019)

The proximal tubule has a remarkable capacity for repair after acute injury, but the cellular lineage and molecular mechanisms underlying this repair response are incompletely understood. Here, we developed a Kim1-GFPCreERt2 knockin mouse line (Kim1-GCE) in order to perform genetic lineage tracing of dedifferentiated cells while measuring the cellular transcriptome of proximal tubule during repair. Acutely injured genetically labeled clones coexpressed KIM1, VIMENTIN, SOX9, and KI67, indicating a dedifferentiated and proliferative state. Clonal analysis revealed clonal expansion of Kim1+ cells, indicating that acutely injured, dedifferentiated proximal tubule cells, rather than fixed tubular progenitor cells, account for repair. Translational profiling during injury and repair revealed signatures of both successful and unsuccessful maladaptive repair. The transcription factor Foxm1 was induced early in injury, was required for epithelial proliferation in vitro, and was dependent on epidermal growth factor receptor (EGFR) stimulation. In conclusion, dedifferentiated proximal tubule cells effect proximal tubule repair, and we reveal an EGFR/FOXM1-dependent signaling pathway that drives proliferative repair after injury.
EXTH-56. MEDULLOBLASTOMAS RESPOND TO CDK4/6 INHIBITION WITH NANOPARTICLE-DELIVERED PALBOCICLIB WITH ALTERED S-PHASE PROGRESSION
Authors: Taylor Dismuke, Chaemin Lim, Timothy Gershon
Journal: Neuro-Oncology (2019)

Abstract CDK4/6 inhibition is a promising therapy for medulloblastoma, one of the most common malignant pediatric brain tumors. To improve pharmacokinetics, we developed a polyoxazoline nanoparticle-encapsulated formulation of the FDA-approved CDK4/6 inhibitor palbociclib (POx-palbo). We then administered POx-palbo to transgenic medulloblastoma-prone GFAP-Cre/SmoM2 mice, to determine the efficacy and mechanisms of action and resistance. We found that POx-palbo slowed tumor progression, but consistently failed to be curative. Further analysis showed that while CDK4/6 inhibition acutely blocked G1 cells from re-entering the cell cycle, this effect wore off within hours of drug administration. However, flow cytometric analysis of EdU uptake hours after palbociclib demonstrated aberrant S-phase with reduced rate of DNA synthesis. This POx-palbociclib-induced alteration of S-phase progression seems to remain true at later time points even when we observed that palbociclib G1/S inhibition began to decrease. Based on these data, we propose that the combinational therapy of POx-palbociclib and S-phase targeting agents will further improve treatment. Faulty tumor cell cycle progression in the presence of Pox-palbociclib may give increased window to target the S-phase for irreversible cell-cycle exit.